Personalis, Inc. 8-K

What Happened
Personalis, Inc. (PSNL) announced on March 13, 2026 that its board appointed Richard Chen as President in addition to his current roles as Executive Vice President, R&D and Chief Medical Officer. The appointment follows a recommendation from CEO Christopher Hall, who previously served as President. Effective April 1, 2026, Dr. Chen’s annual base salary will increase to $570,000 and his performance bonus target will be 70% of his then-current annual base salary. On March 15, 2026 (Grant Date), the company granted equity awards under its 2019 Equity Incentive Plan: an option for 37,500 shares (exercise price = closing price on March 13, 2026) vesting monthly over 36 months, and a restricted stock unit (RSU) award for 6,250 shares with staged vesting beginning six months after the Grant Date.

Key Details

• Appointment date: March 13, 2026; salary increase effective April 1, 2026.
• New annual base salary: $570,000; performance bonus target: 70% of base salary.
• Equity grants (March 15, 2026): option to buy 37,500 shares (36‑month monthly vesting) and 6,250 RSUs (1/6 vests at 6 months, then bi‑annual installments).
• Option exercise price equals closing price of Personalis common stock on March 13, 2026; awards granted under the 2019 Equity Incentive Plan.

Why It Matters
This filing documents a leadership change that keeps technical and clinical leadership in-house while formally adding the President title to Dr. Chen’s responsibilities. For investors, the material items are the increased cash compensation and expanded equity awards — which are intended to retain and incentivize Dr. Chen but may modestly increase compensation expense and could lead to issuance of up to 43,750 shares (37,500 options + 6,250 RSUs) if fully vested/settled and options exercised. The CEO role remains with Christopher Hall; this is an organizational change rather than a CEO succession.